Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver

• Main Authors: Fernando Bessone, Nelia Hernandez, Martin Tagle, Marco Arrese, Raymundo Parana, Nahum Méndez-Sánchez, Ezequiel Ridruejo, Manuel Mendizabal, Lucy Dagher, Fernando Contreras, Eduardo Fassio, Mario Pessoa, Javier Brahm, Marcelo Silva
• Format: Article
• Language: English
• Published: Elsevier 2021-09-01
• Series: Annals of Hepatology
• Subjects: DILI; LATINDILI; ALEH; Hepatotoxicity; HILI; Hepatitis
• Online Access: http://www.sciencedirect.com/science/article/pii/S166526812100020X

Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and dietary supplements) is an uncommon cause of liver disease presenting with a wide range of phenotypes and disease severity, acute hepatitis mimicking viral hepatitis to autoimmune hepatitis, steatosis, fibrosis or rare chronic vascular syndromes. Disease severity ranges from asymptomatic liver test abnormalities to acute liver failure. DILI has been traditionally classified in predictable or intrinsic (dose-related) or unpredictable (not dose-related) mechanisms. Few prospective studies are assessing the real prevalence and incidence of hepatotoxicity in the general population. DILI registries represent useful networks used for the study of liver toxicity, aimed at improving the understanding of causes, phenotypes, natural history, and standardized definitions of hepatotoxicity. Although most of the registries do not carry out population-based studies, they may provide important data related to the prevalence of DILI, and also may be useful to compare features from different countries. With the support of the Spanish Registry of Hepatotoxicity, our Latin American Registry (LATINDILI) was created in 2011, and more than 350 DILI patients have been recruited to date. This position paper describes the more frequent drugs and herbs-induced DILI in Latin America, mainly focusing on several features of responsible medicaments. Also, we highlighted the most critical points on the management of hepatotoxicity in general and those based on findings from our Latin American experience in particular.